Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.49 |
| ▸ | GPR183 | P32249 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 3/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | GPR6 | P46095 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL870089 | 0.87 | GPR119 (0.47) | GPR119GPR183DPP4DPP7CKS1B | |
| Trifluoroacetic Acid SCHEMBL387786 | 0.82 | GPR119 (0.48) | GPR119GPR183CKS1BSKP1SKP2 | |
| Trifluoroacetic Acid SCHEMBL387437 | 0.81 | SLC6A7 (0.46) | GPR119GPR183PTGS2PTGS1SLC6A9 | |
| Trifluoroacetic Acid SCHEMBL387471 | 0.80 | GPR119 (0.65) | GPR119GPR183DPP4DPP7PTGS2 | |
| Trifluoroacetic Acid SCHEMBL387425 | 0.79 | GPR119 (0.50) | GPR119GPR183 | |
| SCHEMBL869277 | 0.78 | GPR119 (0.53) | GPR119GPR183PTGS2PTGS1 | |
| Trifluoroacetic Acid SCHEMBL386540 | 0.78 | FFAR1 (0.56) | GPR119GPR183DPP4DPP7CKS1B | |
| Trifluoroacetic Acid SCHEMBL384405 | 0.76 | LMNA (0.43) | GPR119GPR183DPP4DPP7CKS1B | |
| Trifluoroacetic Acid SCHEMBL388292 | 0.76 | GPR119 (0.41) | GPR119GPR183DPP4DPP7CKS1B | |
| SCHEMBL872405 | 0.75 | PTGS2 (0.49) | GPR119GPR183PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101634-B2 | Bicyclic compounds and use as antidiabetics | GLAXOSMITHKLINE LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITH KLINE BEECHAM CORPORATION a corporation | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | GPR119 1/4885GPR183 1491/4885DPP4 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.